Literature DB >> 24964743

Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms.

Anantha Koteswararao Kanugula1, Paradesi Naidu Gollavilli, Sathish Babu Vasamsetti, Santosh Karnewar, Raja Gopoju, Ramesh Ummanni, Srigiridhar Kotamraju.   

Abstract

Accumulating evidence from in vitro, in vivo, clinical and epidemiological studies shows promising results for the use of statins against many cancers including breast carcinoma. However, the molecular mechanisms responsible for the anti-proliferative and anti-invasive properties of statins still remain elusive. In this study, we investigated the involvement of nitric oxide, iron homeostasis and antioxidant defence mechanisms in mediating the anti-proliferative and anti-invasive properties of hydrophobic statins in MDA-MB-231, MDA-MB-453 and BT-549 metastatic triple negative breast cancer cells. Fluvastatin and simvastatin significantly increased cytotoxicity which was reversed with mevalonate. Interestingly, fluvastatin downregulated transferrin receptor (TfR1), with a concomitant depletion of intracellular iron levels in these cells. Statin-induced effects were mimicked by geranylgeranyl transferase inhibitor (GGTI-298) but not farnesyl transferase inhibitor (FTI-277). Further, it was observed that TfR1 downregulation is mediated by increased nitric oxide levels via inducible nitric oxide synthase (iNOS) expression. NOS inhibitors (asymmetric dimethylarginine and 1400W) counteracted and sepiapterin, a precursor of tetrahydrobiopterin, exacerbated statin-induced depletion of intracellular iron levels. Notably, fluvastatin increased manganese superoxide dismutase (by repressing the transcription factor DNA damage-binding protein 2), catalase and glutathione which, in turn, diminished H2 O2 levels. Fluvastatin-induced downregulation of TfR1, matrix metalloproteinase-2, -9 and inhibition of invasion were reversed in the presence of aminotriazole, a specific inhibitor of catalase. Finally, we conclude that fluvastatin, by altering iron homeostasis, nitric oxide generation and antioxidant defence mechanisms, induces triple negative breast cancer cell death.
© 2014 FEBS.

Entities:  

Keywords:  H2O2; MnSOD; breast cancer; fluvastatin; invasion; iron; nitric oxide; transferrin receptor

Mesh:

Substances:

Year:  2014        PMID: 24964743     DOI: 10.1111/febs.12893

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  19 in total

1.  Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study.

Authors:  Mostafa A Borahay; Kathleen Vincent; Massoud Motamedi; Elena Sbrana; Gokhan S Kilic; Ayman Al-Hendy; Darren Boehning
Journal:  Am J Obstet Gynecol       Date:  2015-03-31       Impact factor: 8.661

2.  VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.

Authors:  Haihong Pu; Qingyuan Zhang; Chunbo Zhao; Lei Shi; Yan Wang; Jingxuan Wang; Minghui Zhang
Journal:  Pathol Oncol Res       Date:  2017-07-25       Impact factor: 3.201

3.  A novel metadherinΔ7 splice variant enhances triple negative breast cancer aggressiveness by modulating mitochondrial function via NFĸB-SIRT3 axis.

Authors:  Praveen Kumar Neeli; Paradesi Naidu Gollavilli; Sreevidya Mallappa; Sai Gayathri Hari; Srigiridhar Kotamraju
Journal:  Oncogene       Date:  2019-12-05       Impact factor: 9.867

4.  Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.

Authors:  Vidula Sukhatme; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme; Pan Pantziarka
Journal:  Ecancermedicalscience       Date:  2015-08-27

5.  Fluvastatin mediated breast cancer cell death: a proteomic approach to identify differentially regulated proteins in MDA-MB-231 cells.

Authors:  Anantha Koteswararao Kanugula; Vishnu M Dhople; Uwe Völker; Ramesh Ummanni; Srigiridhar Kotamraju
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

Review 6.  The Potential Role of Nitric Oxide in Halting Cancer Progression Through Chemoprevention.

Authors:  Huzefa Vahora; Munawwar Ali Khan; Usama Alalami; Arif Hussain
Journal:  J Cancer Prev       Date:  2016-03-30

7.  Estimation of phytochemical constituents and in vitro antioxidant potencies of Brachychiton populneus (Schott & Endl.) R.Br.

Authors:  Riffat Batool; Muhammad Rashid Khan; Moniba Sajid; Saima Ali; Zartash Zahra
Journal:  BMC Chem       Date:  2019-03-21

Review 8.  Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.

Authors:  Nirmala Tilija Pun; Chul-Ho Jeong
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-16

Review 9.  The dual role of iNOS in cancer.

Authors:  Federica Vannini; Khosrow Kashfi; Niharika Nath
Journal:  Redox Biol       Date:  2015-08-24       Impact factor: 11.799

10.  Mitochondria-targeted esculetin alleviates mitochondrial dysfunction by AMPK-mediated nitric oxide and SIRT3 regulation in endothelial cells: potential implications in atherosclerosis.

Authors:  Santosh Karnewar; Sathish Babu Vasamsetti; Raja Gopoju; Anantha Koteswararao Kanugula; Sai Krishna Ganji; Sripadi Prabhakar; Nandini Rangaraj; Nitin Tupperwar; Jerald Mahesh Kumar; Srigiridhar Kotamraju
Journal:  Sci Rep       Date:  2016-04-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.